An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease

Adam M. Brickman, PhD,* Giuseppe Tosto, MD, PhD,* Jose Gutierrez, MD, Howard Andrews, PhD, Yian Gu, PhD, Atul Narkhede, MS, Batool Rizvi, BA, Vanessa Guzman, MS, Jennifer J. Manly, PhD, Jean Paul Vonsattel, MD, Nicole Schupf, PhD, the Alzheimer's Disease Neuroimaging Initiative, and Richard Mayeux, MD

Correspondence

Dr. Mayeux
rpm2@columbia.edu

Neurology® 2018;91:e1402-e1412. doi:10.1212/WNL.0000000000006310

RELATED ARTICLE

Editorial

An MRI biomarker of mixed pathology

Page 682

Abstract

Objective

To develop, replicate, and validate an MRI-based quantitative measure of both cerebrovascular and neurodegeneration in Alzheimer disease (AD) for clinical and potentially research purposes.

Methods

We used data from a cross-sectional and longitudinal community-based study of Medicare-eligible residents in northern Manhattan followed every 18–24 months ($n = 1,175$, mean age 78 years). White matter hyperintensities, infarcts, hippocampal volumes, and cortical thicknesses were quantified from MRI and combined to generate an MRI measure associated with episodic memory. The combined MRI measure was replicated and validated using autopsy data, clinical diagnoses, and CSF biomarkers and amyloid PET from the Alzheimer's Disease Neuroimaging Initiative.

Results

The quantitative MRI measure was developed in a group of community participants ($n = 690$) and replicated in a similar second group ($n = 485$). Compared with healthy controls, the quantitative MRI measure was lower in patients with mild cognitive impairment and lower still in those with clinically diagnosed AD. The quantitative MRI measure correlated with neurofibrillary tangles, neuronal loss, atrophy, and infarcts at postmortem in an autopsy subset and was also associated with PET amyloid imaging and CSF levels of total tau, phosphorylated tau, and β -amyloid 42. The MRI measure predicted conversion to MCI and clinical AD among healthy controls.

Conclusion

We developed, replicated, and validated an MRI measure of cerebrovascular and neurodegenerative pathologies that are associated with clinical and neuropathologic diagnosis of AD and related to established biomarkers.

*These authors contributed equally to this work.

From the Taub Institute for Research on Alzheimer's Disease and the Aging Brain (A.M.B., G.T., H.A., Y.G., A.N., B.R., V.G., J.J.M., J.P.V., N.S., R.M.), The Gertrude H. Sergievsky Center (A.M.B., G.T., H.A., Y.G., J.J.M., N.S., R.M.), and the Departments of Neurology (A.M.B., G.T., J.G., Y.G., J.J.M., N.S., R.M.), Pathology and Cell Biology (J.P.V.), and Psychiatry (R.M.), College of Physicians and Surgeons, and Departments of Biostatistics (H.A.) and Epidemiology (N.S., R.M.), Mailman School of Public Health, Columbia University, New York, NY.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found in the coinvestigators list at links.lww.com/WNL/A692.

Glossary

$A\beta_{1-42}$ = β -amyloid 1-42; **AD** = Alzheimer disease; **ADNI** = Alzheimer's Disease Neuroimaging Initiative; **AUC** = area under the curve; **CI** = confidence interval; **FLAIR** = fluid-attenuated inversion recovery; **GEE** = generalized estimating equations; **LOAD** = late-onset Alzheimer disease; **MCI** = mild cognitive impairment; **p-tau** = phosphorylated tau; **PiB** = Pittsburgh compound B; **ROI** = region of interest; **t-tau** = total tau; **WHICAP** = Washington Heights-Inwood Columbia Aging Project; **WMH** = white matter hyperintensity.

Among postmortem studies of confirmed late-onset Alzheimer disease (LOAD), investigators have frequently observed other types of pathology such as Lewy bodies and cerebrovascular disease. Although the contribution of cerebrovascular disease to LOAD has been debated,^{1,2} cerebrovascular disease is present in up to 70% of patients compared with only 15%–20% of healthy elderly at postmortem examination^{3,4} and mixed pathology is now considered a primary cause of Alzheimer-related dementia.⁵ On MRI, LOAD is manifest by medial temporal lobe and cortical atrophy, but white matter hyperintensities (WMHs) and brain infarcts are also frequent.^{4,6} Structural MRI biomarker studies of LOAD often treat cerebrovascular disease and atrophy as distinct entities, but they coexist more frequently than not and the onset of clinical symptoms in LOAD may be jointly determined by both entities. Because there are no confirmed MRI manifestations of Lewy body pathology and because of the high frequency of cerebrovascular disease in patients with LOAD, the first goal of this study was to develop a quantitative MRI measure that combined aspects of neurodegeneration, including hippocampal volume and cortical thickness in several brain regions^{7,8} and cerebrovascular lesions, including WMH and infarcts^{9,10} based on their relationship with episodic memory function, a common presenting manifestation. The second goal was to determine whether this quantitative MRI measure was associated with the clinical and neuropathologic diagnosis as well as biomarkers related to LOAD.

Methods

Participants

The Washington Heights-Inwood Columbia Aging Project (WHICAP), a prospective, community-based longitudinal study of aging and dementia in northern Manhattan,¹¹ provided individuals recruited from Medicare recipients in 3 waves (1992, 1999, and 2009) followed every 18–24 months. Structural MRI scans were acquired in a total of 1,333 participants in 2 waves. The first wave (WHICAP-1) included 769 participants who were scanned beginning in 2005. The second wave (WHICAP-2) included 564 participants who were scanned beginning in 2011. Participants met the following criteria to be included in the current analyses: (1) available quantitative MRI data; (2) complete neuropsychological evaluations performed at the baseline and follow-up visit contemporaneous with the MRI scan; (3) no evidence of dementia at the clinical follow-up visit prior to the

scan. All but 158 individuals met these criteria, yielding a sample of 1,175 participants (table 1). Compared with WHICAP participants not scanned or included, those who underwent MRI were 3 years younger, but similar in sex and years of education; there were no differences in demographic features between participants in the 2 MRI waves. Forty-two WHICAP participants with MRI data died after the MRI and follow-up data had been acquired and underwent autopsy.

Data from 665 participants were also obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI-1) database (adni.loni.usc.edu) and used to test the observations from the WHICAP cohort in an independent sample.

MRI

In WHICAP-1 ($n = 690$), MRI were obtained on a 1.5T Philips (Best, the Netherlands) Intera scanner. T1-weighted (repetition time 20 ms, echo time 2.1 ms, field of view 240 cm, 256×160 matrix, 1.3 mm slice thickness) and T2-weighted fluid-attenuated inversion recovery (FLAIR) (repetition time 11,000 ms, echo time 144.0 ms, inversion time 2,800, field of view 25 cm, 2 number of excitations, 256×192 matrix with 3-mm slice thickness) images were acquired in the axial orientation. In WHICAP-2 ($n = 485$), MRI images were obtained on a 3T Philips scanner. T1-weighted (repetition time 6.6 ms, echo time 3.0 ms, field of view $256 \times 256 \times 165$, 1.0 mm slice thickness) and T2-weighted FLAIR (repetition time 8,000 ms, echo time 332 ms, field of view $240 \times 240 \times 180$, 0.43 mm slice thickness) images were also acquired axially.

Description of structural MRI and WMH analyses in ADNI were provided earlier.¹² Details of the validation procedures are provided in the e-Methods (doi.org/10.5061/dryad.m8s3r88) and elsewhere (adni.loni.usc.edu). We used the University of California, San Francisco, cross-sectional analysis (UCSFFSX_11_02_15) for cortical thickness and volumetric measurements.

White matter hyperintensities

In WHICAP, whole-brain WMH volumes were quantified from FLAIR images¹³ (figure 1). Briefly, images were skull stripped, and a Gaussian curve was fit to map voxel intensity values. Voxels at least 1.8 and 2.1 SD above the image mean intensity value for the WHICAP-1 and the WHICAP-2 imaging samples, respectively, were labeled. Labeled images were also visually inspected and corrected for false-positive and false-negative errors. The number of labeled voxels was

Table 1 Characteristics of the 2 independent Washington Heights–Inwood Columbia Aging Project imaging groups

	Imaging group 1	Imaging group 2	Combined groups	Combined groups (survival analyses)
No.	690	485	1,175	896
Age, y, mean (SD)	80.30 (5.60)	73.76 (5.62)	77.60 (6.46)	76.77 (6)
Sex, % women	58.0	56.7	57.4	64.4
Education, y, mean (SD)	10.58 (4.90)	12.87 (4.49)	11.61 (4.86)	11.68 (4.76)
MCI, n (%)	122 (17.7)	77 (15.9)	199 (16.9)	NA
AD, n (%)	34 (4.9)	8 (1.6)	42 (3.6)	NA
Conversion to MCI, n (%)	NA	NA	NA	84 (9.4)
Conversion to AD, n (%)	NA	NA	NA	91 (10.2)
Mean time to conversion (SD)	NA	NA	NA	4.3 (3)
WMH volume, log cm ³ , mean (SD)	0.30 (1.58)	0.92 (1.29)	0.56 (1.50)	0.57 (1.45)
Infarct, n (%) with at least one	236 (34.2)	112 (23.1)	348 (29.6)	266 (29.7)
Hippocampus volume, mm ³ , mean (SD)	6,741.04 (943.97)	7,262.34 (993.73)	6,956.22 (997.99)	7,006.56 (959.43)
Cortical thickness, mm, mean SD	2.60 (0.14)	2.71 (0.15)	2.65 (0.15)	2.65 (0.15)

Abbreviations: AD = Alzheimer disease; MCI = mild cognitive impairment; WMH = white matter hyperintensity.

summed and multiplied by voxel dimensions to yield total WMH volumes in cm³ and log transformed.

Infarcts

T2-weighted and T1-weighted images were used to identify brain infarcts visually by 2 raters following a pathology-informed algorithm that segregates chronic brain infarcts from perivascular spaces¹⁴ (figure 1). Infarcts were coded if there was a discrete hypointense lesion ≥5 mm in axial diameter on T1-weighted images; confirmation required a discrete hypointense lesion with an associated hyperintense ring observed in FLAIR images in the same location. This algorithm follows the recommendations of the STRIVE criteria¹⁵ to capture lacunes of presumed vascular origin, in addition to incorporating infarcts greater than 15 mm that are more likely superficial or cortical. When the raters disagreed, adjudication was provided by a stroke neurologist. Infarcts were coded as present if one or more were detected and absent if none was detected. Analyses were repeated with the number of infarcts rather than presence or absence of infarcts as the predictor variable, but the findings remained unchanged (data not shown). We did not consider infarct location.

Hippocampal volume and cortical thickness

Hippocampal volume and cortical thickness in Alzheimer disease (AD)–related signature regions⁸ were quantified on T1-weighted scans with FreeSurfer. As previously described,¹⁶ these measurements included the mean cortical thickness in the following regions of interest: entorhinal cortex, parahippocampus, inferior parietal lobe, pars opercularis, pars orbitalis, pars triangularis, inferior temporal lobe, temporal pole, precuneus, supramarginal gyrus, superior parietal lobe,

and superior frontal lobe (figure 1). FreeSurfer segmentations were visually inspected and manually corrected if necessary by a trained operator.

Neuropsychological evaluation and diagnostic procedures

WHICAP participants were evaluated in either English or Spanish by their choice with validated neuropsychological tests.¹⁷ The primary neuropsychological variable of interest was the memory summary score reflected as the average *z* scores of 3 indicators from the Selective Reminding Test¹⁸: immediate recall, delayed recall, and delayed recognition, adjusted for years of education. We focused on memory function because it is typically the cognitive domain most affected by AD.

A diagnostic consensus panel including neurologists and neuropsychologists adjudicated dementia and its subtypes and used a published algorithm¹⁹ to derive a diagnosis of mild cognitive impairment (MCI) based on standard criteria using neuropsychological, medical, and interview data. The panel was shielded from the MRI scan results.

Data analyses

The overall analytic steps are presented in table 2 and in figure e-1 (doi.org/10.5061/dryad.m8s3r88). Briefly, we first derived a quantitative MRI measure that linearly combined neurodegenerative and cerebrovascular variables based on their association with episodic memory in WHICAP-1. We next applied the same score to the independent WHICAP-2 group to replicate its association. Because of the longitudinal nature of the study, we were able to combine the 2 cohorts to

Figure 1 Examples of primary MRI measures used in the study

(A) White matter hyperintensities (WMHs). The first column shows a single axial slice. The second column displays labeled WMHs in in-house-developed software. The third column illustrates 3D rendering of WMH burden. The top row displays a single participant with relatively mild WMH burden, whereas the bottom row shows a participant with relatively severe WMHs. (B) Examples of observed brain infarcts in a single participant. Top row shows T1-weighted and T2-weighted (fluid-attenuated inversion recovery image) with hyperintense ring around the lesion. The bottom row shows magnification of infarcted areas. (C) 3D rendering of bilateral hippocampus (in yellow) with FreeSurfer in a single participant. FreeSurfer-derived cortical thickness measurements in a single participant demonstrate regions that comprise the Alzheimer disease cortical signature.

Table 2 Sequence of data included, analyses, and relevant outcomes in the study

Step	Sample	Analysis	Outcome
1	WHICAP-1	Association of cerebrovascular (WMH, infarct) and neurodegenerative (hippocampus volume, cortical thickness) with memory	Derivation of quantitative MRI measure based on β weights of each component part
2	WHICAP-2	Application of quantitative MRI measure and examination of its association with memory	Confirmation in an independent sample that the quantitative MRI measure is associated with memory
3	WHICAP-1 + WHICAP-2	Examination of differences among normal controls, individuals with MCI, and individuals with clinical AD in quantitative MRI measure	Confirmation that quantitative MRI measure distinguishes relevant clinical entities
4	WHICAP 1 + WHICAP 2 (autopsy)	Association of quantitative MRI measure with postmortem measurement of AD and vascular pathology	Autopsy confirmation that quantitative MRI measure is associated with both primary AD pathology and markers of cerebrovascular disease
5	ADNI-1	Forward application of the quantitative MRI measure to an independent sample and examination of its association with AD biomarkers and clinical course	Validation of the quantitative MRI measure in an independent sample

Abbreviations: AD = Alzheimer disease; ADNI = Alzheimer's Disease Neuroimaging Initiative; MCI = mild cognitive impairment; WHICAP = Washington Heights-Inwood Columbia Aging Project; WMH = white matter hyperintensity.

examine differences in the scores among subsequent diagnoses (i.e., controls, MCI, LOAD) and to determine whether the score predicted future conversion to MCI or LOAD among healthy controls. We repeated this analysis after limiting the analysis to the WHICAP-2 cohort only.

We examined the association of the MRI measure with neuropathologic features of LOAD and cerebrovascular disease among the 42 participants who came to autopsy. Finally, we computed the MRI score in an independent study (ADNI-1) to test its association with LOAD-specific biomarkers not available in WHICAP and with clinical progression.

In the WHICAP-1 cohort ($n = 690$), multiple linear regression analyses were used with 2 MRI variables reflecting cerebrovascular disease (WMH volume and infarcts) and 2 neurodegenerative variables (hippocampus volume and cortical thickness) as predictors of the memory score (dependent variable). Each participant's raw neuroimaging variables were multiplied by the respective unstandardized β weights generated from the multiple regression analysis. The values were summed to yield a single value for each participant reflecting the linear combination of the cerebrovascular disease and neurodegeneration variables, weighted by their contributions to the memory score, with higher scores indicating more intact memory. The initial regression analysis was repeated with the neurodegeneration and cerebrovascular disease measures entered as separate variables to determine the extent to which inclusion of cerebrovascular disease improved model fit.

The newly derived quantitative MRI measure was then repeated in the WHICAP-2 independent cohort ($n = 485$) using the same β values derived in WHICAP-1. Subsequently, we combined data from the 2 imaging groups and examined

differences in the MRI measure among individuals classified as normal controls, MCI, and LOAD at a subsequent clinical follow-up using analysis of variance.

We conducted multiple Cox proportional hazards models to examine the association of the MRI measure with clinical conversion from control to MCI or LOAD. Here, we compared models that used the derived MRI measure with those that tested each of its component parts separately (i.e., WMH volume, presence of infarct, hippocampus volume, cortical thickness). To define which model performed better, we compared the latter in terms of -2 log-likelihood. We also employed the *glmnet* R package²⁰ to fit an elastic-net regularization path for a Cox model that included all predictors (i.e., WMH volume, presence of infarct, hippocampus volume, cortical thickness, and the quantitative MRI score). The function was run 100-fold for cross-validation and the best value of lambda (such that error is within 1 standard error of the minimum) was used to identify the best set of predictors.

Autopsy validation

Forty-two WHICAP participants with MRI data came to autopsy. We examined the relationship between the quantitative MRI measure and key pathologic findings: neuritic amyloid plaques, neurofibrillary tangles, large and small vessel infarcts, and atrophy. Because measurements were made in several brain regions, the 2 regions with the greatest average severity ratings across participants were selected for the primary autopsy outcome. Multiple regression analysis, correcting for the time interval between MRI and date of death, were conducted to examine the relationship between the quantitative MRI measure and each pathologic outcome separately. We subsequently recalculated the quantitative MRI measure by including only neurodegenerative factors

(hippocampal volume and cortical thickness), repeated the regression analyses with this score, and compared the variance explained (R^2) between models. We also repeated the analyses with each individual MRI variable entered separately to determine whether the weighted, linear combination in the MRI measure was more strongly associated with pathology than any of its component parts. Neuritic plaques were rated on a 5-point scale ranging from 0 (i.e., no plaques observed) to 4 (i.e., 20 or more plaques observed) regionally. Neurofibrillary tangles were similarly rated on a 5-point scale (0, 0 tangles noted; 4, ≥ 15 tangles noted). Regional atrophy was rated on a 4-point scale, ranging from absent to severe. The number of brain infarcts on gross examination was recorded.

Alzheimer's Disease Neuroimaging Initiative

ADNI has included data from over 50 sites across the United States and Canada. Study procedures and the follow-up duration for ADNI-1 have been described in the protocol (adni.loni.usc.edu) and in the e-Methods (doi.org/10.5061/dryad.m8s3r88). A standardized and validated MRI protocol for image acquisition was implemented across ADNI sites.²¹ MRI data acquisition took place on 1.5T systems. T1-weighted volumetric sequences were acquired in the sagittal orientation. A proton density/T2-weighted fast spin echo sequence was acquired in the axial orientation. Sites included in the ADNI protocol passed rigorous scanner validation tests and scan acquisitions for each subject included a fluid-filled phantom (adni.loni.usc.edu). WMH quantification procedures have been described previously.¹² The T1-, T2-, and proton density-weighted MRI scans were coregistered and skull stripped.^{22,23} After bias field correction,²⁴ WMH were detected based on corresponding proton density, T1, and T2 intensities; the prior probability of WMH; and the conditional probability of WMH based on the presence of WMH at neighboring voxels. Total WMH volumes were derived by summing and multiplying the number of labeled voxels by voxel dimensions. The methods for infarcts assessment in ADNI are reported in ADNI_UCD_MRI_Infarct_Assessment_Method_201130609_.pdf file downloadable at adni.loni.usc.edu.

CSF β -amyloid 1-42 ($A\beta$ 1-42), total tau (t-tau), and phosphorylated tau 181 (p-tau181) concentration measurements were made with the microbead-based multiplex immunoassay, the INNO-BIA AlzBio3 RUO test (Fujirebio, Ghent, Belgium),²⁵ on the Luminex platform. Full procedures can be found within ADNI_UPENN_Biomarker_Master_Overview_Shaw_Figurski_Waligorska_Trojanowski_CSF_20160704a.pdf, downloadable at adni.loni.usc.edu.

The Pittsburgh compound B (PiB)-PET add-on study began its third year of ADNI-1 in May 2009. A total of 103 baseline PiB-PET studies were completed at 14 participating ADNI PET centers in 19 elderly cognitively normal controls (mean age 78 years), 65 individuals with MCI (mean age 75 years), and 19 patients with LOAD (mean age 73 years).²⁶ Regional assessment of the PiB-PET data involved sampling 13 different brain areas with an automated region of interest (ROI)

template method. In addition, an average value of 4 ROIs was calculated for each participant. Positive amyloid scans (PiB+) were defined when the standardized uptake value ratio exceeded a value of 1.50 in the average of the 4 ROIs. This PiB+ cutoff value was based on studies in a large group of cognitively normal controls studied at the University of Pittsburgh.²⁷

From the initial 871 ADNI-1 participants, data from 665 (76%) were available for analyses. Full demographics for the ADNI sample are reported in table e-1 (doi.org/10.5061/dryad.m8s3r88). We selected the same 4 MRI variables and applied the β values derived from the WHICAP analysis to derive an identical quantitative MRI measure. We then tested the association between the quantitative MRI measure and the clinical diagnosis, CSF biomarkers, and amyloid-PET imaging measures for LOAD. First, we fit an ordinal regression model with the 3 diagnostic categories at baseline (i.e., healthy control, MCI, LOAD). We then restricted the analyses to participants with MCI, the largest diagnostic group in ADNI. We used generalized estimating equations (GEE) to examine the association between the quantitative MRI measure and rate of change in Clinical Dementia Rating²⁸ sum of boxes score. Finally, we used linear regression to examine the relationship of the quantitative MRI measure with PET and CSF biomarker values. All ADNI analyses were adjusted for sex, age at baseline, *APOE* ϵ 4 allele, and intracranial volume.

Standard protocol approvals, registrations, and patient consents

All participants provided written informed consent. Ethical approval for this study was obtained from the Columbia University committee.

Data availability

Data are available upon request along with analysis coding. Inquiries should be submitted to the WHICAP data request portal: cumc.co1.qualtrics.com/jfe/form/SV_6x5rRy14B6vpqN.

Results

Derivation of the quantitative MRI measure

The overall model used to test the association between the quantitative MRI measure and memory was significant ($R = 0.362$, $F_{4,568} = 21.26$, $p < 0.001$) with little evidence of collinearity between predictor variables (variance inflation factors ranged from 1.06 to 1.13). When each MRI variable was entered separately, the inclusion of WMH and infarcts significantly improved the model fit (R^2 change = 0.015, $F = 8.97$, $p < 0.001$). The results of this analysis and the independent relationship between each neuroimaging variable and episodic memory are shown in table 3.

The unstandardized β weights were then combined linearly to derive the quantitative MRI measure for each participant using the following equation:

Table 3 Derivation of the quantitative MRI measure based on association of key neuroimaging variables with memory

Variable	Unstandardized coefficient ^a		95% Confidence interval		Standardized coefficient
	β	SE	Lower bound	Upper bound	
WMH volume ^b	-0.088	0.027	-0.141	-0.036	-0.138
Infarct	-0.045	0.0090	-0.221	0.131	-0.021
Hippocampus volume	0.00027	0.000044	0.00018	0.000353	0.247
Cortical thickness	1.03	0.29	0.458	1.60	0.143

Abbreviation: WMH = white matter hyperintensity.

^a Unstandardized beta weights were generated based on the independent association of WMH, presence of infarct, hippocampal volume, and cortical thickness with a memory summary score (with education residualized out).

^b White matter hyperintensity volume was log transformed.

$$\begin{aligned} \text{Quantitative MRI measure} = & -0.088 * \log \text{ WMH volume} \\ & + -0.045 * \text{infarct} \\ & + 0.00027 * \text{hippocampus volume} \\ & + 1.03 * \text{cortical thickness} \end{aligned}$$

The resulting quantitative MRI measure was normally distributed (data not shown). Although the relationship between presence of infarcts and episodic memory was not statistically significant, we elected to retain the variable in the derivation of the MRI measure because it represents a characteristic cerebrovascular measure. However, the relatively weak association with memory still results in the small contribution of infarction to the overall score across individuals.

Relationship of the quantitative MRI measure to memory and diagnostic outcomes

Higher quantitative MRI measure was observed in those with better episodic memory performances in both WHICAP groups with moderate effect sizes (table e-2, doi.org/10.5061/dryad.m8s3r88). On follow-up, compared with healthy controls, patients with MCI had lower scores, and those with LOAD had the lowest scores ($F = 47.45$, $p < 0.001$; all pairwise comparisons: $p < 0.001$; figure e-2).

Survival analyses

Among the WHICAP-1 and WHICAP-2 participants, 896 were free of dementia or MCI at the time of the MRI scan. Subsequently, 175 (19.5%) of these participants transitioned to either MCI or LOAD. Full description of the subcohort used for survival analyses is reported in table 1. Lower hippocampus volume, lower cortical thickness, and higher WMH predicted conversion to MCI or LOAD. Presence of infarcts did not predict conversion. Finally, the MRI score predicted conversion to MCI or LOAD and showed the lowest likelihood test score across all the models tested (see table 4 for full results). Because the MRI measure was originally derived in the WHICAP-1 cohort, we repeated the analyses restricting the sample to the WHICAP-2 cohort. We confirmed that the MRI score significantly predicted conversion to MCI or LOAD and fits the best model, as compared with each predictor alone (table 4).

The results from the *glmnet* analyses are reported in the e-Methods (doi.org/10.5061/dryad.m8s3r88). The optimal λ value ($\lambda = 0.08$) and a cross-validated error plot used for the evaluation of our model can be found in figure e-3. Only the quantitative MRI score was included in the final model at the optimal λ value. In figure e-4, we plotted each predictor as a curve that describes the path of its coefficient against the L1-norm of the whole coefficient vector at as λ varies.

Autopsy validation

Participants with lower quantitative MRI measures had more neurofibrillary tangle pathology in hippocampal subfields

Table 4 Cox regression models in the overall sample and in the WHICAP-2 only sample

Predictors ^a	HR	95% CI	p Value	-2 log likelihood
WHICAP-1 and WHICAP-2				
Hippocampus	1.56	1.33–1.84	<0.001	2,069.794
Cortical signature	1.26	1.09–1.46	<0.001	2,088.698
WMH	1.37	1.19–1.59	<0.001	2,080.049
Infarcts	1.30	0.95–1.78	0.096	2,095.158
MRI score	1.68	1.44–1.96	<0.001	2,056.671
WHICAP-2 only				
Hippocampus	1.42	1.06–1.91	0.02	418.572
Cortical signature	1.15	0.83–1.58	0.40	422.989
WMH	1.41	0.99–1.99	0.05	420.106
Infarcts	1.35	0.69–2.66	0.38	447.848
MRI score	1.45	1.09–1.95	0.01	417.777

Abbreviations: CI = confidence interval; HR = hazard ratio; WHICAP = Washington Heights–Inwood Columbia Aging Project; WMH = white matter hyperintensity.

^a All predictors have been z scored; to further clarify the comparison, WMH, hippocampus volume, cortical signature, and MRI score have been inverted to create a “risk” association with the outcome.

CA1 ($\beta = -1.24$, $p = 0.001$) and CA2/CA3 ($\beta = -0.89$, $p = 0.039$). Lower quantitative MRI measures were observed in those participants with more atrophy in temporal ($\beta = -0.720$, $p = 0.005$) and parietal ($\beta = -0.552$, $p = 0.015$) lobes, and with higher frequency of pathologically defined infarcts ($\beta = -1.57$, $p = 0.012$; figure 2). The mean time interval between the MRI scan and autopsy was 5.35 (SD 3.20) years; this interval was not associated with any of the pathologic outcomes apart from temporal lobe atrophy ($\beta = 0.43$, $p < 0.001$). The quantitative MRI measure accounted for more variance when cerebrovascular variables were included compared with when neurodegenerative factors were included alone: neurofibrillary pathology ($R^2 = 0.272$ and 0.124 vs 0.124 and 0.104) and infarcts ($R^2 = 0.00$ vs 0.009) but for not atrophy ($R^2 = 0.404$ and 0.177 vs 0.395 and 0.219). The quantitative MRI measure did not vary with neuritic plaque burden in frontal or parietal lobes (respectively, $\beta = -0.327$, $p = 0.434$; $\beta = -0.397$, $p = 0.347$).

ADNI-1 analysis

As in the WHICAP cohorts, participants with MCI or LOAD diagnosis had lower MRI measure scoring ($\beta = -1.49$; 95% confidence interval [CI] -1.70 to -1.27 , $p < 0.001$). Those with higher MRI measure values also showed higher

CSF-derived A β 42 ($\beta = 0.26$, 95% CI 0.15 to 0.36 , $p < 0.001$), lower t-tau ($\beta = -0.33$, 95% CI -0.44 to -0.22 , $p < 0.001$), and lower p-tau ($\beta = -0.34$, 95% CI -0.45 to -0.23 , $p < 0.001$). In the GEE model restricted to participants with MCI, those with higher MRI measures were characterized by slower rate of change of the Clinical Dementia Rating scale sum of boxes ($\beta = -0.84$, 95% CI -1.08 to -0.59 , $p < 0.001$). Finally, the quantitative MRI measure was associated with PET-derived amyloid, as a continuous variable ($\beta = -0.14$, 95% CI -0.23 to 0.05 , $p = 0.003$) or using a threshold for positivity (PiB+ vs PiB-: 30, 95% CI 0.13 to 0.69 , $p = 0.004$; figure 3) Table e-3 (doi.org/10.5061/dryad.m8s3r88) summarizes these results.

Discussion

The main focus of this investigation was the development of a quantitative MRI measure reflecting the joint contributions of WMH, presumed to be an indication of small vessel cerebrovascular pathology, brain infarcts, and neurodegeneration to the clinical and pathologic diagnosis of LOAD. The quantitative MRI measure was derived in a community-based cohort and replicated. Validation of the quantitative MRI measure was completed using autopsy data and clinically proven biomarkers

Figure 2 Relation between quantitative MRI measure and brain pathology

Each patient's specific brain pathology was rated on a scale from 0 to 5 as described in the Methods. The quantitative MRI measure for each patient is represented by a black dot within the rating of the neuropathologic findings. The red dot represents the mean quantitative MRI measure within each category.

Figure 3 Scatterplot representing the distribution of the quantitative MRI measure in relation to the PET–Pittsburgh compound B (PiB) average uptake in the Alzheimer’s Disease Neuroimaging Initiative–1 cohort

for LOAD. The MRI measure predicted conversion in controls to MCI or LOAD. These results confirm and augment the role of both neurodegeneration and cerebrovascular pathology in LOAD, and suggest the possibility of capturing both in a single valid and reliable MRI-based measure.

The MRI measure we developed combined quantitative measures of neurodegeneration, brain infarcts, and WMH, which can reflect cerebrovascular disease, each weighted by their contribution to episodic memory. Because the MRI measure comprised neurodegenerative changes such as cortical thinning and hippocampal atrophy, well-validated MRI biomarkers for LOAD, it is not surprising that it correlated with memory and measures of pathologic findings in LOAD. It is important to point out that in all analyses, the addition of the WMH and brain infarcts also significantly increased the strength of association with episodic memory and with the clinical and pathologic outcomes. The goal here was not to develop a diagnostic biomarker for LOAD but rather a quantitative metric combining the weighted contributions of neurodegeneration and cerebrovascular disease. Despite the fact that the MRI measures were weakly correlated, there was no indication of statistical interaction among them, indicating that each was additive to the overall score. The area under the curve (AUC) for the MRI score and its components was similar (data available in figure e-5, doi.org/10.5061/dryad.m8s3r88: MRI score 0.76; hippocampus volume 0.75; cortical thickness 0.74; WMH volume 0.73; infarct volume 0.72),

placing the overall MRI score in the “good” category for biomarkers. The mean sensitivity at 89% and specificity at 55% in this article is also comparable to CSF measures of A β , tau, and p-tau.²⁹ In fact, a review of table 5 in that article indicates that each CSF measure (A β , tau, and p-tau) yielded similar AUCs as each MRI measure in our study.

Our study indicated that the MRI measure was also associated with both LOAD neuropathology and related PET and CSF biological markers, an important validation step. These findings augment the observations showing a link between the presence of cerebrovascular vascular risk factors in midlife and LOAD-specific biological markers in later life.³⁰ While others have considered the contribution of cerebrovascular factors to LOAD risk and clinical presentation to be additive, our study is unique for several reasons. First, the derivation of the MRI score weighted each cerebrovascular and neurodegenerative factor by its relevance to a meaningful cognitive phenotype: episodic memory. Second, the MRI measure combines both cerebrovascular and neurodegenerative factors into a single conceptual framework that closely reflects the mixed pathology of LOAD.³¹ Third, we were able to replicate our findings in independent datasets and validate the resulting MRI measure using direct pathologic measurements and LOAD-specific PET and CSF biomarkers.

While there is now substantial evidence that cerebrovascular disease plays a role in LOAD, there is considerable debate

about the mechanistic link. Atherosclerosis involving both large and small arteries is associated with a twofold risk of dementia.^{32,33} Endothelial and pericyte damage, inflammatory changes in vessels, atherosclerotic plaques, and microglial activation within endothelial cells can affect brain function and structure. An alteration of the blood–brain barrier, resulting from macrovascular and microvascular damage, can result in oxidative stress, inflammation, and cerebral hypoperfusion,³⁴ which have been implicated in AD.³⁵ A neurovascular hypothesis for LOAD has been proposed that posits the presence of cerebrovascular disease leads to a breakdown of the blood–brain barrier, altering the clearance of A β and p-tau, which results in neuronal dysfunction, neurodegeneration, and dementia.³⁶ However, it is also possible that cerebrovascular pathology may be secondary to an alteration in A β clearance with A β accumulation and neurodegeneration. Thus, a breakdown in the blood–brain barrier or other vessel changes results in cerebrovascular pathology and hypoperfusion,³⁷ which has been observed with multiple imaging modalities of LOAD. Our study was unable to establish causality between cerebrovascular factors and LOAD, but it does suggest the strong possibility that cerebrovascular factors contribute to the clinical manifestations and neurodegeneration in LOAD.

While the prevalence of LOAD and related dementia has increased due to increase life expectancy, recent studies^{38–42} indicate an inconsistent, but declining trend in incidence rates possibly related to a reduction in cardio-cerebrovascular risk factors. However, adjusting for such a reduction did not completely explain the change in incidence rates.^{41,42} Nonetheless, vascular risk factors and cerebrovascular disease could represent a potential avenue for LOAD risk modification.

The current study has limitations. The field strength for the MRI in the first WHICAP imaging group differed from that in the second group (1.5T vs 3.0T), but we were able to subsequently apply the MRI measure from the former group to the latter with good reliability, suggesting minimal effect on the outcome. Differences in field strength may affect measurement precision for the radiologic variables of interest, but should not alter the relationship between the variables and key outcomes. The MRI variables used in the study such as cerebrovascular disease, quantified by volume of WMH and infarcts, and as neurodegeneration, quantified by hippocampus volume and loss of cortical thickness, may lack specificity. For example, WMH could be a reflection of neurodegeneration,⁴³ although the vast majority of previous work would suggest a vascular origin, and cortical thickness can certainly be affected by cerebrovascular disease. Indeed, increased burden of WMH was associated with risk for familial early-onset AD, and progression of symptoms, and is elevated among individuals with autosomal dominant, fully penetrant mutations prior to symptoms.^{13,44–46}

Our autopsy analyses were on 42 individuals. This limitation is somewhat mitigated by the use of biomarker data from the

ADNI cohort. We included frequently used measures of cerebrovascular disease, including WMH and radiologic infarcts. We were unable to include others such as microbleeds and microinfarcts because they were only available in a few participants and we did not have sufficient spatial resolution to identify cortical microinfarcts reliably. The association of infarcts with episodic memory was weak, resulting in a relatively small weighting applied to presence of infarction in the final derivation of the MRI measure. Neurodegeneration and cerebrovascular disease can affect each other, making the 2 processes difficult to separate. However, this possibility does not detract from our work and, in fact, highlights the possibility of synergism between the 2 processes.

It is likely that the mixed pathologies of WMH and brain infarcts, reflecting cerebrovascular pathology, and the neurodegeneration manifest by focal atrophy and cortical thinning in LOAD are part of a continuum in which the onset and clinical manifestations of LOAD are jointly determined. This research approach might help to advance our understanding of this complex disease process and will help develop potential targets for treatments or preventive measures that are more precise for the individual patient.

Author contributions

Conception and design of the study: A.M.B., G.T., N.S., R.M. Acquisition and analysis of data: A.M.B., G.T., J.G., H.A., Y.G., A.N., B.R., V.G., J.M., J.P.V., N.S., R.M. Drafting the manuscript or figures: A.M.B., G.T., N.S., R.M.

Study funding

Supported by NIH (P01AG007232, R01AG037212, RF1AG054023, R01AG034189, and R56AG034189) and the National Center for Advancing Translational Sciences, NIH, through grant UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Data collection and sharing for this project was also funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH grant U01AG024904) and DOD ADNI (Department of Defense award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is

providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Received January 25, 2018. Accepted in final form June 28, 2018.

References

- Diaz JF, Merskey H, Hachinski VC, et al. Improved recognition of leukoaraiosis and cognitive impairment in Alzheimer's disease. *Arch Neurol* 1991;48:1022–1025.
- Hachinski V. Stroke and Alzheimer disease: fellow travelers or partners in crime? *Arch Neurol* 2011;68:797–798.
- Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. *J Neuropathol Exp Neurol* 2003;62:1287–1301.
- Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease: lessons from pathology. *BMC Med* 2014;12:206.
- Bennett DA. Mixed pathologies and neural reserve: implications of complexity for Alzheimer disease drug discovery. *PLoS Med* 2017;14:e1002256.
- Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain* 2013;136:2697–2706.
- Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207–216.
- Dickerson BC, Wolk DA. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. *Neurology* 2012;78:84–90.
- DeBette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. *Stroke* 2010;41:600–606.
- Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol* 2007;6:611–619.
- Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. *Jama* 1998;279:751–755.
- Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. *Inf Process Med Imaging* 2009;21:239–251.
- Brickman AM, Zahodne LB, Guzman VA, et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. *Neurobiol Aging* 2015;36:27–32.
- Gutierrez J, Elkind MSV, Dong C, et al. Brain perivascular spaces as biomarkers of vascular risk: results from the Northern Manhattan study. *AJNR Am J Neuroradiol* 2017;38:862–867.
- Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013;12:822–838.
- Zahodne LB, Manly JJ, Narkhede A, et al. Structural MRI predictors of late-life cognition differ across African Americans, Hispanics, and whites. *Curr Alzheimer Res* 2015;12:632–639.
- Siedlecki KL, Manly JJ, Brickman AM, Schupf N, Tang MX, Stern Y. Do neuropsychological tests have the same meaning in Spanish speakers as they do in English speakers? *Neuropsychology* 2010;24:402–411.
- Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. *Neurology* 1974;24:1019–1025.
- Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. *Ann Neurol* 2008;63:494–506.
- Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. *J Stat Softw* 2011;39:1–13.
- Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging* 2008;27:685–691.
- Birdsill AC, Kosciak RL, Jonaitis EM, et al. Regional white matter hyperintensities: aging, Alzheimer's disease risk, and cognitive function. *Neurobiol Aging* 2014;35:769–776.
- Wolz R, Julkunen V, Koikkalainen J, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. *PLoS One* 2011;6:e25446.
- DeCarli C, Murphy DG, Teichberg D, Campbell G, Sobering GS. Local histogram correction of MRI spatially dependent image pixel intensity nonuniformity. *J Magn Reson Imaging* 1996;6:519–528.
- Olsson A, Vanderstichele H, Andreassen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. *Clin Chem* 2005;51:336–345.
- Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. *Alzheimers Dement* 2010;6:221–229.
- Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch Neurol* 2008;65:1509–1517.
- Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. *Neurology* 1997;48:1508–1510.
- Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. *Alzheimers Res Ther* 2018;10:32.
- Gottesman RF, Schneider AL, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. *JAMA* 2017;317:1443–1450.
- Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol* 2017;134:171–186.
- Luchsinger JA, Brickman AM, Reitz C, et al. Subclinical cerebrovascular disease in mild cognitive impairment. *Neurology* 2009;73:450–456.
- Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's coordinating center. *Neurology* 2005;64:494–500.
- Di Marco LY, Venneri A, Farkas E, Evans PC, Marzò A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer's disease: a review of endothelium-mediated mechanisms and ensuing vicious circles. *Neurobiol Dis* 2015;82:593–606.
- Toth P, Tarantini S, Csiszar A, Ungvari Z. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. *Am J Physiol Heart Circ Physiol* 2017;312:H1–H20.
- Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev* 2011;12:723–738.
- Zhao Y, Gong CX. From chronic cerebral hypoperfusion to Alzheimer-like brain pathology and neurodegeneration. *Cell Mol Neurobiol* 2015;35:101–110.
- Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382:1405–1412.
- Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. *Neurology* 2013;80:1888–1894.
- Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. *Alzheimers Dement* 2011;7:80–93.
- Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. *N Engl J Med* 2016;374:523–532.
- Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. *Neurology* 2012;78:1456–1463.
- McAleese KE, Walker L, Graham S, et al. Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. *Acta Neuropathol* 2017;134:459–473.
- Brickman AM. Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. *Curr Neurol Neurosci Rep* 2013;13:415.
- Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. *Arch Neurol* 2008;65:1202–1208.
- Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. *Ann Neurol* 2016;79:929–939.